Intercytex raises £12M in new venture round

The UK's Intercytex has raised £12 million in new venture capital. Avlar BioVentures, Merlin Biosciences, 3i, Cambridge Gateway Partnership, NIF Ventures and Scottish Equity Partners all participated in the round. The financing will be used to complete Phase III trials of ICX-PRO, Intercytex's active woundcare product, take ICX-TRC, its hair regeneration product, through later stage clinical trials and to move ICX-SKN, a living skin replacement, into the clinic. "We are extremely pleased to have raised this considerable sum which allows us to significantly advance all our projects," said Nick Higgins, Intercytex's CEO.

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.